J&J team shows off 'break­through' BC­MA CAR-T da­ta, and that could cause a big headache at blue­bird and Bris­tol-My­ers

Just hours af­ter J&J’s on­col­o­gy team bragged about scor­ing a break­through ther­a­py des­ig­na­tion for their BC­MA CAR-T drug, they pulled the wraps off of the mul­ti­ple myelo­ma da­ta for JNJ-4528 that im­pressed the FDA. And it’s easy to see why they may well be on a short path to a land­mark ap­proval — which may well be mak­ing the ri­val team at blue­bird/Bris­tol-My­ers more than a lit­tle ner­vous.

Fol­low­ing up on some at­ten­tion-grab­bing da­ta ini­tial­ly pre­sent­ed by their Chi­nese de­vel­op­ment part­ners at Leg­end 2 years ago dur­ing AS­CO, in­ves­ti­ga­tors say they tracked some jaw-drop­ping re­sults that con­firmed the ear­ly promise of a ther­a­py that’s shak­ing up a crowd­ed field led by blue­bird bio.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER